BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
GlideTech materials are available in several standard base resins and offer customization options for specific applications
Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
